Abionic Signs Agreement to Optimize Asthma Management in the United States with Innovative, Rapid Point of Service Testing

BIOPOLE, LAUSANNE, Switzerland –

Abionic SA, developer of proprietary nanotechnology-based proprietary fast disruptive diagnostic solutions, and Genentech, a division of the Roche Group, today announced the signing of a strategic agreement for the development and supply of nanotech products. a panel of asthma tests for in vitro diagnostics (IVD) AbioSCOPE POC®Platform known by Abionic in the United States. The abioSCOPE POC® Abionic, a compact and ultra-fast medical device with patented nanofluidic technology, determines blood levels of immunoglobulin E (IgE), an underlying cause of allergic asthma. The platform provides lab-quality results in five minutes from a single drop of blood to the POC, allowing rapid diagnosis and immediate initiation of treatment.

Under this agreement, Abionic will fulfill all the requirements for the pre-market process of a specific asthma test group in order to quantify the total IgE and the levels of IgE. IgE for 5 key allergens associated with allergic asthma throughout the year. Genentech will cover all clinical and regulatory costs of testing.

"At Abionic, we focus on providing true, patient-centric diagnostic solutions, i.A quick and reliable test, available anytime, anywhere and whenever a patient needs it. The agreement with Genentech, a leader in the development of new drugs for respiratory diseases, including allergic asthma, is a major step towards a more personalized and accurate diagnosis, "said Dr. Nicolas Durand , General Manager of Abionic.

"Uncontrolled allergic asthma has a significant impact on people's lives; the number of cases has increased dramatically over the last 40 years – millions of people are diagnosed each year in the US." This partnership is linked our commitment to personalized medicine AbionSCOPE® from Abionic enables a personalized POC test that facilitates the diagnosis of patients. "Ivan Märki, Abionic's Technical Director.

Tests of allergic asthma

Asthma is a chronic inflammatory disease of the airways that can cause breathing problems, coughing and wheezing. In its most severe form, it can lead to life-threatening exacerbations that require urgent medical attention. Allergic asthma is a subtype of asthma caused by exposure and hypersensitivity to allergens. Allergic asthma is diagnosed by medical history, physical examination, lung function tests, skin tests and / or laboratory tests revealing sensitivity to allergens. Current asthma diagnoses do not allow professionals to obtain immediate and quantitative results from the POC.1

The kit for allergic asthma on abioSCOPE® is a POC test that provides both total IgE and IgE of the main allergenic allergens, i. Dog and cat hair, Alternaria alternata mushroom, domestic mite and German cockroaches. The first IgE result is available in just 5 minutes and a complete allergic profile in less than 8 minutes from a drop of capillary blood. Abionic 's technology makes it possible to develop up to 14 allergy and asthma tests in a single kit that allows the panel to be adapted to the different clinical needs of the world.

About allergic asthma

In the United States, about 25 million people suffer from asthma, including about 60% of allergic asthma.2 Allergic asthma is one of the most common long-term illnesses in children.3 That's about 6.2 million people under 18 or one in 12 American children.4 The American Academy of Pediatrics estimates that between 70% and 80% of asthmatic children of school age also have allergies that are among the most common causes of asthma.5

About Abionic

Founded in 2010, Abionic is a Swiss medical technology company that has developed a revolutionary nanofluidic technology that provides physicians with a fast, simple and universal diagnostic tool.

Abionic's advanced nanotechnology enhances the efficiency and versatility of standard ELISA tests in order to provide optimal treatment options for COP, with the potential for reducing current biological techniques of macroscopic scale. at the nanoscale in a multi-analyte environment.

Abionic's In Vitro Diagnostic Platform (IVD) provides lab-quality results in a minute from a single drop of blood to the POC, allowing for personalized diagnosis and immediate treatment.

Other certified products already exist in the areas of sepsis, allergy and iron deficiency, so that new goals for the future IVD market can be explored.

For more information, visit https://www.abionic.com.

All trademarks used or mentioned in this release are protected by law.

credentials

  1. Swiss allergy center. Allergy Testing https://www.aha.ch/swiss-allergy-centre/info-on-allergies/good-to-know/allergy-tests/?oid=1572&lang=en

  2. Asthma cases of atopic origin: results of the third national survey on health and nutrition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291202/

  3. United States Centers for Disease Control and Prevention. What is asthma? http://www.cdc.gov/asthma/faqs.htm. Access on June 30, 2016.

  4. United States Centers for Disease Control and Prevention. Current national prevalence of asthma. http://www.cdc.gov/asthma/most_recent_data.htm. Access on June 21, 2016.

  5. American Academy of Pediatrics. Healthy Children.org. Guide on allergies and asthma in your child. https://www.healthychildren.org/English/health-issues/conditions/allergies-asthma/Pages/Allergies.aspx. Access on June 30, 2016.

Source: Business Wire